$125MSeries D, 29 September 2025
Funds the pivotal Phase 3 trial of VGA039 in von Willebrand disease.
- Amount
- $125M
- Stage
- Series D
- Announced
- 29 September 2025
- Lead
- Sanofi Ventures
- Other investors
- Viking Global Investors, Janus Henderson Investors, Frazier Life Sciences, GordonMD Global Investments
- Use of funds
- Funds the pivotal Phase 3 trial of VGA039 in von Willebrand disease.
- Checked
- Announced by the company
- Sources
- Star Therapeutics raises $125M Series D (date approx) businesswire.com
Star Therapeutics raises $125M Series D (date approx) news.crunchbase.com